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Abstract
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Current therapies to treat asthma and other airway diseases primarily include anti-inflammatory
agents and bronchodilators. Anti-inflammatory agents target trafficking and resident immunocytes
and structural cells, while bronchodilators act to prevent or reverse shortening of airway smooth
muscle (ASM), the pivotal tissue regulating bronchomotor tone. Advances in our understanding of
the biology of G protein-coupled receptors (GPCRs) and biased agonism offers unique
opportunities to modulate GPCR function that include the use of pepducins and allosteric
modulators. Recent evidence suggests that small molecule inhibitors of Gαq as well as pepducins
targeting Gq-coupled receptors can broadly inhibit contractile agonist-induced ASM function.
Given these advances, new therapeutic approaches can be leveraged to diminish the global rise in
morbidity and mortality associated with asthma and chronic obstructive pulmonary disease.

Summary
Author Manuscript

Despite considerable research efforts, asthma and COPD remain substantial therapeutic challenges
and contribute globally to increasing morbidity and mortality. Bronchodilators reverse or prevent
shortening of airway smooth muscle, and remain principal drugs in both prophylactic management
and treatment of obstructive airway diseases. Over the past two decades, advances in management
of the non-severe asthma/COPD patient have been limited to modest refinements in traditional
bronchodilator drugs. Recent advances in GPCR biology and structural protein biochemistry offer
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unparalleled opportunities to develop novel therapeutic approaches that either activate or inhibit
GPCR function. Coupling these discoveries to leveraging delivery systems that specifically target
the airways may profoundly affect the morbidity and mortality in airway diseases.

Introduction

Author Manuscript

Profound advances in the fields of receptor biology and pharmacology have now identified
novel approaches to modulate the function of G protein-coupled receptors (GPCRs), the
largest super family of cell-surface receptors in the human genome [1,2]. Although the
concept of rational drug design has existed for decades, only recently have structural biology
and molecular modeling capabilities advanced this concept beyond the theoretical stage.
Providing a further boost is the related and exploding field of biased ligand pharmacology,
whose insights have greatly advanced our understanding of qualitative GPCR signaling. One
intriguing discovery 16 years ago was the identification that receptor intracellular surface
loops that interact with G proteins can be targeted by N-terminal lipidated peptides
(pepducins) to modulate GPCR signaling and potentially serve as therapeutics [1,3].
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Current therapies to treat asthma and other airway diseases primarily include antiinflammatory agents and bronchodilators. Anti-inflammatory agents target trafficking and
resident immunocytes and structural cells, while bronchodilators act to prevent or reverse
shortening of airway smooth muscle (ASM), the pivotal tissue regulating bronchomotor
tone. Unfortunately, about 50% of patients with asthma have inadequate control with current
therapeutics [4]. Despite some refinements in the duration and specificity of β2-adrenergic
receptor (β2AR) agonists and in the use of antagonists of contractile GPCRs in asthma,
continued refinement may yield diminishing returns and truly novel approaches will be
needed to overcome current limitations and address the needs of patients not served by
currently available therapies.
Most bronchodilators are GPCR ligands which exert their action by either promoting prorelaxant or inhibiting pro-contractile signaling. This underscores the importance of the
competitive balance of pro-relaxant and pro-contractile GPCR signaling in regulating ASM
contractility and airway resistance in obstructive lung diseases [5–7]. Airway resistance is
also affected by structural changes in the airways (airway remodeling) and pulmonary
architecture as well as tissue mechanics, but GPCR ligands acting on ASM have the
strongest impact on changes in airflow.

Author Manuscript

Increased levels of endogenous contractile GPCR agonists have been associated with
allergic airway inflammation, leading to increased ASM contraction and airflow obstruction.
One strategy to ameliorate this is to inhibit pro-contractile GPCR signaling by administering
a small molecule antagonist of a pro-contractile receptor. This approach may be suboptimal
or entirely ineffective when multiple GPCRs are activated to contract ASM. Treatment with
β-agonists relaxes airways by antagonizing pro-contractile GPCRs at several loci in airway
smooth muscle including transmembrane receptor signaling, calcium mobilization and flux,
and distal regulation of contractile filaments through regulation of myosin light chain kinase/
phosphatase (MLCK/MLCP) activity. Therefore, use of β-agonists has an inherent
advantage over selective antagonists of pro-contractile GPCRs as β-agonists dilate/protect
Curr Opin Pharmacol. Author manuscript; available in PMC 2019 January 24.
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airways irrespective of the type of pro-contractile stimulus. Even though inhaled β-agonists
are the mainstay therapy for acute bronchospasm and combined long-acting β-agonist
(LABA) and corticosteroid treatment is the cornerstone of asthma and chronic obstructive
pulmonary disease (COPD) maintenance therapy, concerns about β-agonist efficacy and
safety have persisted for decades. Chronic β-agonist use has been associated with β2AR
tachyphylaxis [8–10], loss of asthma control [11–13], and death [14–17]. Although
associations of chronic β-agonist use with adverse events have not been uniquely observed
in all studies [18–20], the need for understanding mechanisms involved in detrimental
effects of β-agonists on lung physiology and pathology remains.

Author Manuscript

Fortunately, recent basic science research in GPCR biology and pharmacology has
discovered novel modes of GPCR signaling and regulation that potentially explains the
complex effects of existing drugs while offering the promise of new, more efficacious drugs.
In this review, we summarize studies based on newfound paradigms in GPCR biology to (1)
identify strategies capable of making existing asthma and COPD drugs better; and (2)
develop new drugs that work by distinctly different mechanisms.

Diverse receptor conformations are linked to differential signaling events;
arrestins and biased ligands can influence the qualitative nature of
signaling

Author Manuscript
Author Manuscript

GPCR ligands are often characterized based on their efficacy, be it positive or negative, to a
specific signaling pathway that is in turn linked to a specific cellular function. However, it
has been apparent for some time that there exists a much greater complexity of ligandreceptor interactions, and recent studies that attempt to explain ‘why’ are probably only
scratching the surface of the regulatory phenomena that enable receptor dexterity. Numerous
GPCRs exhibit significant diversity in their capacity to activate multiple signaling pathways,
linked to either other G proteins or in a G protein-independent manner. Some ligands engage
a receptor to induce a distinct receptor conformation capable of activating one signaling
pathway while inhibiting another pathway. This phenomenon, referred to ‘functional
selectivity’ or ‘biased agonism’, has been demonstrated for a number of GPCRs. The 5HT2CR ligand SB 242084, promoted 5-HT2cR-mediated PLC activation [21] but inhibited 5HT2cR-mediated activation of phospholipase A2 (PLA2) and the subsequent release of
arachidonic acid (AA)[22]. In a somewhat striking observation, studies by Stout et al. [23]
show that the agonist efficacy of ligands does not correlate with the capacity to induce
desensitization of the different signaling pathways, therefore suggesting differential
regulation of desensitization by various ligands of the 5-HT2cR. Similar observations have
been made for 5-H2A, µ-opioid, somatostatin, and chole-cystokinin receptors, where the
level of efficacy of various ligands is dissociated from the ability to promote agonist-induced
receptor desensitization (reviewed in [24]). Studies of D2 [25] and D1 dopamine [26], H1
histamine [27] and V2 vasopressin [24,28] receptors have identified ligands that exhibit
differential abilities in pathway activation and receptor desensitization and trafficking.
Agonism bias is also exhibited towards G protein-independent signaling. Arrestins have now
become established as the most prominent G protein-independent signaling molecules
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(Figure 1). Arrestins were initially characterized as important regulators of receptor
desensitization and internalization; arrestins are recruited to activated GPCRs where they
subsequently hinder G protein recruitment and facilitate receptor internalization via clathrincoated pits [29]. More recently arrestins have been proposed to act as signaling scaffolds and
a large body of evidence now supports the capacity of various ligands to promote β-arrestindependent signaling events in absence of G protein activation. ICI 118,551 and propranolol,
both inverse agonists for β2AR-mediated Gs activation, have been shown to induce β2ARmediated arrestin-dependent p42/p44 activation [30]. This differential efficacy has been
observed for other receptors including the V2 vasopressin receptor [30] and the
angiotensin-1 receptor [31]; which both have the ability to activate p42/p44 via β-arrestin
recruitment independent of Gq activation when bound to their respective biased ligands.

Author Manuscript

Collectively, these findings demonstrate that GPCR ligands can induce a range of distinct
receptor conformations which determine signaling outcomes. Wisler et al. [32] identified
carvedilol as having a unique profile out of a panel of 16 βAR ligands: it is an inverse
agonist for βAR-mediated Gs signaling but stimulates receptor phosphorylation, recruits
beta-arrestin, promotes receptor internalization and activates p42/p44 in an arrestindependent manner. The authors hypothesize that this unique profile contributes to the
effectiveness of carvedilol in treatment of heart failure. Current evidence suggests that
biased agonism, through either choice of orthosteric ligands, use of allosteric modulators,
direct targeting of G proteins, or manipulation of GRK and arrestin function, can be realized
to tailor GPCR function and improve our ability to modulate airway inflammation and/or
promote bronchodilation.

Novel strategies co-opting heterotrimeric G protein regulatory mechanisms
Author Manuscript

can regulate ASM contraction
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GPCRs in ASM represent attractive therapeutic targets for multiple reasons, including the
ability to readily target them with selective agents (inhaled small molecules). Approaches for
targeting downstream elements have some conceptual appeal; for example, broad-based
strategies for inhibiting the heterotrimeric Gq protein could be an effective means of
negating the effects of all pro-contractile agonists in the inflamed airway, and overcoming
the limitations of monotherapies such as tiotropium and montelukast [33]. To date, however,
such approaches have not materialized as sufficiently selective and deliverable reagents have
not been developed. However, recent studies have determined experimental approaches for
manipulating heterotrimeric G protein function, many discovered as a consequence of our
improved understanding of GPCR-G protein coupling, RGS function, and structural biology
of heterotrimeric G proteins. We feel such approaches can be adapted to inhibit Gq
signaling, and consequently Gq-mediated contraction, in ASM.
Multiple strategies designed to interdict GPCR-Gq or Gq-PLC coupling as a means of global
inhibition of Gq-coupled receptor signaling may offer new therapeutic approaches in airway
diseases. Strategies include pepducins (Figure 2) that function as broad-based antagonists of
Gq signaling, lipidated Gαq peptides that selectively disrupt GPCR/Gq coupling, and small
molecule inhibitors of Gbg-mediated signaling. Importantly, most of these strategies employ

Curr Opin Pharmacol. Author manuscript; available in PMC 2019 January 24.

Panettieri et al.

Page 5

Author Manuscript

lipidated peptides that are amenable to delivery to the airway and ASM cells, and are more
likely to specifically engage their target than are gene delivery approaches that are often
required for targeting protein– protein interactions.
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Our initial efforts to bias signaling with lipidated peptides focused on the development of
pepducins derived from the intracellular regions of a GPCR [1]. The Benovic laboratory
found that pepducins from the third intracellular loop (ICL3) of the β2AR could mediate Gsbiased signaling [34] while pepducins from ICL1 mediated arrestin-biased signaling [35].
Some ICL3 pepducins were found to stabilize a conformation of the β2AR that interacted
selectively with Gs while other ICL3 pepducins directly activated Gs. While receptorspecific ICL3 pepducins had properties attributable to Gs-biased signaling such as reduced
β2AR endocytosis and desensitization, these molecules were not effective at attenuating
carbachol-induced contraction in human precision-cut lung slices [36]. Nevertheless, given
the ability of pepducins to bias Gs-signaling, efforts are underway to identify small
molecules that would have a similar bias. Initial efforts should involve screening compounds
using the β2AR as a target to identify Gs-biased agonists, Gs-biased positive allosteric
modulators and arrestin-biased negative allosteric modulators.

Author Manuscript
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While stimulation of Gs signaling serves as a primary strategy for treating asthma, Gq
signaling is also an important target. However, while inhibiting human ASM contraction can
serve as an effective means of treating asthma, one problem is that there are many Gqcoupled receptors that are activated in asthma or COPD including the M3 muscarinic
acetylcholine, cysteinyl leukotriene, H1 histamine, thromboxane, endothelin-A/B and others.
To assess whether broad inhibition of Gq signaling is effective at attenuating ASM
contraction, Carr et al. utilized several strategies to inhibit Gq including the Gαq specific
inhibitor FR900359 (aka UBO-QIC) and a Gq-coupled receptor pepducin that appears to
function as an antagonist [36]. FR900359 was confirmed as a selective Gq inhibitor which
does not substantially effect Gs, Gi or G12/13 activity. Both the P4pal-10 pepducin and the
small molecule FR900359 were effective at inhibiting Gq-mediated signaling and growth in
primary HASM cells, while only FR900359 effectively inhibited agonist-promoted airway
contraction in human precision cut lung slices [36]. In addition the pepducin P4pal-10,
derived from the intracellular loop of the protease-activated receptor (PAR) 4, was
determined to function as a broad-based Gq inhibitor in HEK293 and human ASM cells
(Figure 3; data from Carr et al. [36].) P4pal-10 was shown to inhibit Gq coupling to
receptors including PAR1, M3 muscarinic acetylcholine (M3 mAChR), and H1 histamine
(H1R), whereas no direct effects on Gq or the ability to antagonize GPCRs coupled to Gs
were observed. Consistent with its ability to inhibit M3 mAChR and histamine H1R
coupling to Gq, p4Pal-10 inhibited ASM contraction induced by carbachol and histamine.
These studies, using two approaches to inhibit Gq signaling, indicate that inhibition of Gq
signaling at the receptor locus may be a feasible approach to treat several pathophysiological
processes in airway disease.
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Figure 1.
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General concept of biased agonism. An unbiased agonist will induce balanced signaling by
promoting coupling to G proteins and GRKs/ β-arrestins. This typically will promote G
protein-dependent and β-arrestin-dependent signaling as well as GPCR desensitization,
endocytosis and degradation. In contrast, a biased agonist will induce a receptor
conformation that will enable selective activation of G protein — dependent or G proteinindependent (arrestin) signaling. In addition, for those GPCRs capable of coupling to
multiple G proteins, biased ligands may preferentially promote GPCR coupling to a specific
G protein. Accordingly, biased agonism can dramatically influence the functional
consequences of receptor activation, and influence receptor desensitization.
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A proposed mechanism of action for pepducin effects on GPCR function. The lipidated
nature of the peptides fosters pepducin incorporation into the outer leaflet of the
plasmalemma. The fluidity of the pepducin to move within the plasma membrane can
stabilize the GPCR conformation and/ or prevent G protein interaction to promote or inhibit
intracellular signaling [1].
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Figure 3.

Pepducins as inhibitors of GPCR-Gq signaling. Agonist-promoted calcium mobilization was
monitored by Fura-2 AM fluorescence in agonist-stimulated HEK293 (PAR1-AP, ATP,
Carbachol) and human ASM cells (Bradykinin, Histamine) pretreated for 1 min with
indicated concentrations of P4pal-10. Data from Carr et al. Mol Pharmacol 2016; values are
mean ± SD, n = 3.
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